About Oculis

Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye.
Oculis has developed a drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop.


Oculis’ most advanced product candidate is dexamethasone cyclodextrin nanoparticle eye drops, DexNP, in two indications; diabetic macular edema (DME) and intermediate/posterior uveitis. In both instances phase II human data show good clinical effect.
DexNP would be the first eye drops to treat DME and intermediate/posterior uveitis. Available drugs for DME are invasive, either intravitreal injections or implants and current treatments for uveitis involve intravitreal injections or oral corticosteroids.

Get in touch

For enquiries about Oculis please contact us at: info@oculispharma.com.